Scientists at Imagion Biosystems, along with our collaborators, continue to push back the boundaries of detection limits in our quest to improve on the early detection of cancer. Our recent research study, “Development of advanced signal processing and source imaging methods for superparamagnetic relaxometry,” published January 10th in the journal Physics in Medicine and Biology, describes their improvements in the way magnetic field signals arising from superparamagnetic relaxation are collected and interpreted to yield information about the quantity and location of nanoparticles bound to cancer cells. This research will enable the development of cancer detection systems that are more accurate, more sensitive, and simpler to use.
Read Development of advanced signal processing and source imaging methods for superparamagnetic relaxometry at IOP Publishing.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce